Depo-Provera MDL Causation Ruling Still Pending as Pfizer's Settlement Leaves ~1,280 Claims Out

The Depo-Provera MDL causation ruling is still outstanding, and about 1,280 claims are waiting on it

Judge M. Casey Rodgers convenes the monthly case management conference in MDL No. 3140 in Pensacola today, 18 September 2026, with the two motions that actually decide whether this litigation has merit — the Rule 702 general causation challenges and Pfizer's summary judgment motion on federal preemption — still under advisement. The Depo-Provera MDL causation ruling matters more now than it did before the parties settled, not less: a Global Settlement signed on 21 July 2026 is understood to reach roughly 80% of the 6,403 actions pending as of 1 September 2026, which leaves on the order of 1,280 federal claims whose entire future rests on rulings the settlement deliberately does not resolve.

That inversion is the story. In the ordinary arc of a pharmaceutical Mass Tort, a global deal makes the gatekeeping fight moot; the parties stipulate to dismissal, the Daubert Challenge is denied as moot, and the Multidistrict Litigation (MDL) winds down through a claims process. Here the opposite happened. The court kept the general causation record open, reset rather than cancelled the evidentiary hearing, and then substituted three new pilot plaintiffs for the original five once those five became settlement-eligible. Each of those steps is a decision to preserve an adversarial vehicle for the population the Master Settlement Agreement excludes. Practitioners who read this docket as "settled, therefore over" are reading the wrong 80%.

What happened at the Depo-Provera MDL case management conference on 18 September 2026?

Today's proceeding is the regularly scheduled case management conference set by Pretrial Order No. 28, entered 21 November 2025, which fixed the 2026 conference calendar at monthly intervals — 17 April, 15 May, 26 June, 17 July, 21 August, 18 September, 16 October, 20 November and 18 December — each at 9:00 a.m. Central Time in Courtroom 5 of the United States Courthouse, One North Palafox Street, Pensacola. Judge Rodgers presides with Magistrate Judge Hope T. Cannon. Under the court's standing practice, leadership on both sides filed a joint agenda letter on 14 September, four days ahead of the conference, and that letter is circulated not only to the MDL court but to the coordinating state courts in New York, Delaware and California.

That last detail is worth pausing on, because it tells you what kind of conference this is. A joint agenda letter copied to three state coordinating courts is the instrument of a judge managing a national inventory rather than a single federal docket. The state-court Depo-Provera filings are not bound by the MDL's Rule 702 ruling, but they are informed by it, and the settlement program's registration architecture has to account for claimants whose cases sit in Pensacola, in New York, in Delaware and in California simultaneously. The agenda letter is how the federal court keeps the four tracks legible to one another.

What a conference of this kind covers is predictable in structure even when the specific agenda is not public: the status of the settlement registration and the Claims Administrator's intake, the census of newly filed and newly transferred actions, any outstanding Plaintiff Fact Sheet (PFS) compliance disputes, the schedule for the substituted pilot cases, and the posture of the motions taken under advisement. What it will not produce, on the available record, is the ruling itself. Judge Rodgers took the general causation and preemption questions under advisement rather than deciding them from the bench, and nothing in the public docket indicates that either has been decided as of today's date.

How a global settlement and an undecided Depo-Provera MDL causation ruling came to share one docket

The sequence matters, because the ordering is what created the residue. The Judicial Panel on Multidistrict Litigation (JPML) centralized the Depo-Provera litigation in the Northern District of Florida in February 2025, when the inventory was a few dozen actions. By March 2025 there were 78. Judge Rodgers frontloaded the two cross-cutting questions that decide a pharmaceutical MDL — whether the science supports General Causation under Federal Rule of Evidence 702, and whether the Failure to Warn claims are preempted because the Food and Drug Administration would not have permitted the warning plaintiffs say was owed — and set a pilot-case schedule to litigate both on a common record.

Date	Event
February 2025	JPML centralizes the Depo-Provera litigation as MDL No. 3140 in the Northern District of Florida, Pensacola Division, before Judge M. Casey Rodgers
March 2025	78 actions pending
December 2025	FDA approves supplemental labeling adding meningioma risk to the warnings and patient counseling sections for Depo-Provera CI and Depo-SubQ Provera 104
21 November 2025	Pretrial Order No. 28 sets the 2026 monthly case management conference schedule
2 February 2026	2,098 actions pending
22 April 2026	Plaintiffs move to exclude four Pfizer general causation experts — Drs. Kurt Barnhart, Craig Horbinski, Emily Levitan and Rachel Masch
15 June 2026	Pretrial Order No. 30A records a global settlement agreement in principle between plaintiffs' lead counsel Christopher Seeger and Pfizer Inc., Pharmacia LLC and Pharmacia & Upjohn Company LLC; bellwether and pretrial deadlines vacated; the Rule 702 hearing is reset rather than cancelled
27 July 2026	Rule 702 general causation hearing held in Pensacola, having moved from its 24-26 June setting
21 July 2026	Master Settlement Agreement signed
3 August 2026	6,294 actions pending (JPML monthly report)
5 August 2026	BrownGreer PLC appointed settlement administrator
1 September 2026	6,403 actions pending
18 September 2026	Case management conference; Rule 702 and preemption motions remain under advisement
November 2026	Settlement registration expected to close
7 December 2026	Former trial date for the first pilot case, Blonski v. Pfizer; deadlines vacated
Q1 2027	First settlement payments projected

Read the two June and July entries together and the architecture becomes obvious. Pretrial Order No. 30A vacated the bellwether machinery — trial date, pretrial deadlines, the apparatus of getting Blonski in front of a jury — while leaving the evidentiary hearing on the calendar. A court that thought the settlement would dispose of the MDL would have vacated the hearing too. Judge Rodgers moved it by roughly a month and held it. The stated reason, consistent across the reporting, is that the global agreement once finalized would not resolve all cases in the MDL, because only plaintiffs meeting the eligibility criteria the parties negotiated would have the opportunity to participate.

Has Judge Rodgers ruled on general causation in the Depo-Provera MDL?

No. As of 18 September 2026 the court has not issued the Depo-Provera MDL causation ruling. The Rule 702 general causation hearing was held in Pensacola on 27 July 2026, after being reset from its original 24-26 June setting by the 15 June settlement order, and the motions were taken under advisement. Pfizer's parallel motion for summary judgment on federal preemption was likewise postponed rather than decided, and remains pending.

There is some inconsistency in secondary coverage on this point that practitioners should be aware of. Several litigation trackers describe the causation hearing as held on 27 July; a smaller number describe the court as set to hear Pfizer's general causation and Rule 702 challenges on 18 September. The corroborated event is the 27 July hearing. Today's proceeding is the regular monthly conference fixed by Pretrial Order No. 28 nearly a year in advance, not a newly calendared evidentiary hearing, and no public source states that a ruling has issued. Anyone advising a client on this docket should confirm the position from the docket itself rather than from any summary, including this one.

The substance of the fight is narrower than the headline "does Depo-Provera cause meningioma" suggests. Plaintiffs' 22 April motions did not merely defend their own experts; they attacked Pfizer's. The motion directed at Dr. Kurt Barnhart argues that his opinion — that no reliable evidence of a causal association between Depo-Provera and meningioma existed before 2024 — has no bearing on general causation at all, fails Federal Rule of Evidence 401's relevance threshold, and therefore cannot help the factfinder under Rule 702(a); it argues separately that the opinion is unreliable under Rule 702(c) because it did not engage the early biomechanism evidence, and notes a Rule 26(a) disclosure problem arising from the deposition. Companion motions target Drs. Craig Horbinski, Emily Levitan and Rachel Masch on related grounds.

That posture — plaintiffs moving to exclude defense experts on a general causation record — is the signature of a plaintiff group that likes its science. It is also, in a post-settlement world, a group protecting the residue. Every defense expert excluded narrows what Pfizer can say to a jury in the cases the settlement does not buy.

What is the Depo-Provera settlement and what is it worth?

The Depo-Provera settlement is a private, aggregate resolution between Pfizer and MDL leadership, recorded as an agreement in principle in Pretrial Order No. 30A on 15 June 2026 and reduced to a signed Master Settlement Agreement on 21 July 2026. The defendants are Pfizer Inc., Pharmacia LLC and Pharmacia & Upjohn Company LLC; plaintiffs' lead counsel is Christopher Seeger. BrownGreer PLC was appointed settlement administrator on 5 August 2026.

Its value is not public, and no responsible figure can be given. The Master Settlement Agreement is confidential. The Settlement Matrix — the tier structure, the medical proof requirements, the documentation thresholds, the per-claimant allocations — has not been released. Individual firm pages circulate per-claim estimates in the range of $150,000 to $500,000, but those are marketing-side projections offered as estimates rather than terms disclosed by the parties, and no aggregate fund figure has been stated by anyone with access to the document. Readers encountering a confident total for this settlement should treat it as inference.

What is known about the shape of the deal is structural rather than numerical. It is a claims-administered program with a registration window rather than a class settlement, so there is no Rule 23 fairness hearing, no class notice and no opt-out right in the class-action sense; participation is by election through counsel, governed by the eligibility criteria the parties negotiated. That design is common in pharmaceutical MDL resolutions and it is what produces the eligibility gap discussed below: a Rule 23 settlement class is defined to include everyone who fits, whereas a private aggregate program is defined to include everyone who qualifies, and the two are not the same set.

The drivers of individual value in a program of this kind are not mysterious even when the matrix is sealed. Tier placement in meningioma settlements ordinarily turns on tumor size and location, whether resection or radiotherapy was required, whether the claimant suffered permanent neurological or visual deficit, the cumulative duration and frequency of injections, age at diagnosis, and documented economic loss in the form of medical expenses and lost earnings. Those factors are why the firm-side estimates span a range wide enough to be nearly uninformative: a single injection series followed by an incidentally discovered, surgically managed tumor and a decade of quarterly dosing followed by craniotomy and permanent deficit do not belong in the same tier, and no public document says how many tiers exist between them.

Who qualifies for the Depo-Provera settlement and who is left out?

Roughly 80% of the plaintiffs then pending in the MDL are expected to be eligible to participate, a figure consistently reported across litigation trackers and firm updates since the agreement in principle. The corollary is that roughly 20% are not — and on a base of 6,403 pending actions as of 1 September 2026, that is approximately 1,280 federal cases.

The criteria that draw the line have not been published. What can be said is what ordinarily drives eligibility in a meningioma program of this kind: documented and sufficiently prolonged exposure to medroxyprogesterone acetate, a confirmed meningioma diagnosis with imaging or pathology, temporal sequencing between exposure and diagnosis, and a claim that is timely under the applicable Statute of Limitations or preserved by a Tolling Agreement. A claimant may fail any one of these and still have filed in good faith. Short-duration users, claimants whose product identification rests on pharmacy records that do not survive audit, claimants with a competing radiation or genetic explanation for the tumor, and claimants whose diagnosis predates the exposure window will tend to fall outside a negotiated matrix regardless of the underlying merit of the science.

That is the population the Depo-Provera MDL causation ruling now governs. They are not a rump of frivolous filings; they are the cases whose facts do not fit the criteria two sophisticated parties negotiated in private to cap Pfizer's exposure. Their claims live or die on general causation and preemption, decided on a record built for everyone.

What happens to Depo-Provera claims that are not eligible for the settlement?

They proceed in the MDL, and they are bound by the court's Rule 702 general causation ruling whenever it issues. Judge Rodgers has indicated that MDL plaintiffs who did not seek permission to submit separate general causation experts or additional briefing will be bound by the court's ruling on general causation. That is the mechanism that converts one evidentiary decision into a dispositive event for approximately 1,280 actions.

The arithmetic runs in two directions and practitioners should hold both:

Outcome of the Rule 702 ruling	Effect on the ~1,280 non-eligible actions	Effect on the ~5,120 eligible actions
Plaintiffs' general causation experts admitted; Pfizer's excluded in whole or part	Claims survive to Specific Causation and case-specific workup; leverage for a second-tranche resolution on different criteria	Largely irrelevant; participants have elected into the program and will be paid on the matrix
Plaintiffs' experts admitted; Pfizer's also admitted	Claims survive but face a contested causation trial; value depends on individual workup, exposure duration and damages	Irrelevant
Plaintiffs' general causation experts excluded	Summary judgment follows as a matter of course; the residue is extinguished in the federal forum	Irrelevant — the settlement is not contingent on the ruling
Preemption granted on failure-to-warn theories	Failure to Warn claims fall; Design Defect and any surviving theories must carry the case alone	Irrelevant

The asymmetry in the right-hand column is the point. A plaintiff who registered for the settlement has no exposure to the ruling. A plaintiff who did not qualify has total exposure to it, and no participation right to fall back on. That is an unusual distribution of risk within a single docket, and it is why the substituted pilot cases exist.

State-court filings in New York, Delaware and California are a partial exception. A federal court's Rule 702 ruling does not bind a state court applying its own evidentiary standard — Frye in some jurisdictions, a state analogue of Rule 702 in others — and a non-eligible claimant with a viable state forum and a timely claim has an alternative that a claimant already transferred into the MDL does not. That is one reason the joint agenda letter goes to those three courts.

Does Pfizer's preemption defense still matter after the settlement?

Yes, and arguably more than the causation motion, because Preemption (Products) is a pure question of law that can be decided without a jury and applied across the entire residue at once. Pfizer moved for summary judgment on the theory that the failure-to-warn and design defect claims are preempted because the FDA rejected the meningioma warning the plaintiffs say should have been added. Judge Rodgers postponed the ruling rather than issuing it.

The defense has a complication of Pfizer's own making. The corroborated sequence is that Pfizer submitted an initial meningioma warning proposal that the FDA did not accept, then submitted a revised warning request that the agency approved in December 2025, resulting in supplemental labeling that added meningioma risk to the warnings section and to the patient counseling information for both Depo-Provera CI and Depo-SubQ Provera 104. An approved label change cuts against the "clear evidence" showing that impossibility preemption requires: the agency did, in the end, permit a meningioma warning.

The countervailing argument is about timing and about newly acquired information. Preemption in this posture turns on whether the manufacturer could unilaterally have strengthened the label under the changes-being-effected regulation at the time the plaintiff was injured, which in turn depends on whether there was newly acquired information then that would have supported the warning. Pfizer's expert position — the one plaintiffs moved to exclude through Dr. Barnhart — that no reliable evidence of the association existed before 2024 is not an accident of expert selection. It is the evidentiary foundation of the preemption defense. If no reliable evidence existed before 2024, there was no newly acquired information to act on, and the label the plaintiffs wanted could not lawfully have been added when it mattered.

That is why the Rule 702 motion and the preemption motion are the same motion wearing different clothes, and why a court would sensibly take both under advisement together. It is also why plaintiffs attacked a defense expert on relevance grounds under Rule 401 rather than only on reliability: the "no reliable evidence before 2024" opinion does work in the preemption analysis that it cannot do in a general causation analysis, and plaintiffs are trying to strip it from the record in both places at once.

The pilot-case substitution is the clearest signal on this docket

The original pilot group in MDL 3140 comprised five cases — Toney, Blonski, Schmidt, Wilson and Arceo — selected precisely because they were the vehicles for litigating preemption and general causation on a common record. All five became eligible for the settlement. Judge Rodgers approved the substitution of three new pilot plaintiffs in their place.

Consider what that order does not do. It does not dissolve the pilot structure. It does not stay the MDL pending the claims process. It does not defer the cross-cutting questions until the registration window closes. It replaces settling plaintiffs with non-settling plaintiffs so that the cross-cutting questions keep an adversary. A court that expected the settlement to resolve the litigation would have had no reason to go looking for three new plaintiffs.

The substitution also reveals something about the residue's quality. Pilot cases are chosen, not drawn at random; a court selecting replacement pilots for a general causation and preemption record will choose cases that present those questions cleanly. That implies the non-eligible population contains claims the court regards as adequate vehicles for the central legal questions — which is a different proposition from a population of unqualified or unsupported filings.

For anyone modeling this litigation, the substitution is the most informative order on the docket since Pretrial Order No. 30A. It is the court telling the parties that the merits questions will be answered whether or not the settlement closes.

Is the Blonski v. Pfizer bellwether trial still going ahead in December 2026?

Not as originally scheduled. Blonski v. Pfizer was set as the first trial in MDL 3140 for 7 December 2026, and its pretrial deadlines — along with the remaining bellwether deadlines — were vacated by Judge Rodgers after the parties reported the global agreement in principle in June 2026. Blonski is among the five original pilot cases that became settlement-eligible and were replaced in the pilot pool.

What that means practically is that the first Bellwether Trial in this MDL, if one occurs at all, will involve a substituted pilot plaintiff on a schedule that has not been set and cannot be set until the Rule 702 and preemption motions are decided. There is no live trial date in MDL 3140 today. Any source stating that a Depo-Provera trial begins in December 2026 is repeating a schedule that the court vacated three months ago.

The sequencing is worth stating plainly because claimants and referral counsel routinely misread it: the vacated trial date is not evidence that the litigation weakened, and the settlement is not evidence that the trial would have failed. The deadlines were vacated because trying a case that had just settled is pointless, and the pilot pool was reconstituted because the questions the trial would have framed still need answering for everyone else.

When is the Depo-Provera settlement registration deadline and when will payments start?

Registration into the settlement program is expected to be completed in November 2026, with a registration deadline reported as 30 November 2026. Claims processing and the first settlement payments are projected to begin in the first quarter of 2027. BrownGreer PLC, appointed on 5 August 2026, administers the program.

Stage	Timing	Status
Agreement in principle (Pretrial Order No. 30A)	15 June 2026	Complete
Master Settlement Agreement executed	21 July 2026	Complete
Settlement administrator appointed (BrownGreer PLC)	5 August 2026	Complete
Registration window	through 30 November 2026	Open
Eligibility determination and claim review	Late 2026 into 2027	Pending
First payments	Q1 2027	Projected
Rule 702 general causation ruling	No date	Under advisement
Preemption summary judgment ruling	No date	Under advisement

Two features of that table deserve comment. First, the registration window closes before either merits ruling is expected, which means claimants must elect whether to register without knowing whether the claims of those who cannot register will survive. That ordering is favorable to the defendant: it maximizes participation by pricing uncertainty into every election. Second, the claim review stage is where the 80/20 line is actually drawn. The percentage is an estimate of eligibility, not a count of determinations, and the size of the residue will not be known with precision until BrownGreer completes intake.

Claimants should also expect the ordinary frictions of an administered program: documentation demands that exceed what the Plaintiff Fact Sheet (PFS) required, Medical Lien resolution before disbursement, a Common Benefit Fund assessment on recoveries, and the possibility that funds move through a Qualified Settlement Fund (QSF) with its own tax and timing consequences. None of that is unusual. All of it lengthens the gap between "registered" and "paid."

How many Depo-Provera lawsuits are pending in MDL 3140?

6,403 actions were pending in MDL No. 3140 as of 1 September 2026. The growth curve is steep even by pharmaceutical MDL standards:

Report date	Pending actions	Change
March 2025	78	—
2 February 2026	2,098	+2,020 in eleven months
3 August 2026	6,294	+4,196 in six months
1 September 2026	6,403	+109 in one month

The deceleration between the August and September reports is the most telling figure in the table. A docket adding roughly 700 cases a month through the first half of 2026 added 109 in the month after the Master Settlement Agreement was signed. That is what a negotiated eligibility matrix does to the filing incentive: once the criteria exist, even privately, referral counsel can estimate whether a new claimant qualifies, and claims that plainly do not qualify stop being worth a filing fee. It is also why the residue is unlikely to grow its way to significance. The non-eligible population is roughly fixed at what was already on file.

The December 2025 FDA label change sits behind the earlier part of the curve. Supplemental labeling adding meningioma risk to the warnings section and patient counseling information for Depo-Provera CI and Depo-SubQ Provera 104 gave claimants a discoverable, dateable regulatory event, and the filing surge through the first half of 2026 tracks it closely. The same label change, as discussed above, is the fact that complicates Pfizer's preemption position.

What it means for plaintiffs' firms, defense counsel, funders and claimants

For plaintiffs' firms with MDL inventory. The economics of a Depo-Provera book now split on a line drawn in a confidential document. Eligible files convert on the matrix with administrative work and lien resolution. Non-eligible files are contingent on a Rule 702 ruling that could extinguish them entirely, and carry the Specific Causation and case-workup costs of individually litigated product cases if they survive. Firms that valued a book on aggregate case count before 15 June 2026 are carrying a valuation that no longer describes the asset. The practical step is triage against the eligibility criteria as they emerge from BrownGreer's intake, and an honest reserve against the possibility that the residue is worth zero.

For defense counsel and corporate risk functions. This docket is a working demonstration that a private aggregate settlement does not buy peace from the merits. Pfizer bought approximately 80% of an inventory and is still litigating general causation and preemption against substituted pilot plaintiffs, on a record that will be cited in every state-court Depo-Provera case and in the next meningioma or hormonal-product litigation. Where a program-based resolution is preferred to a class settlement for its flexibility, the trade is that the excluded tail remains adversarial and the court may actively preserve its ability to litigate.

For litigation funders. Third-Party Litigation Funding exposure in this MDL is now binary in a way it was not in May. A facility secured against an undifferentiated case count has been silently restructured by the eligibility criteria into a senior tranche that pays on a schedule and a junior tranche that pays nothing unless a pending evidentiary motion goes the right way. Underwriting written before June 2026 that did not model a partial settlement with an excluded residue is mispriced. The relevant diligence question is no longer "how many cases" but "how many eligible cases, and what is the workup cost of the remainder."

For claimants outside the settlement. The immediate consequence is that nothing resolves quickly. There is no trial date, no ruling date, and no participation right. The claims remain live and bound by whatever the court decides on general causation. Where a timely state-court claim is available in a jurisdiction applying a different evidentiary standard, that forum is not governed by the federal ruling — a point that matters most to claimants in New York, Delaware and California, where coordinated proceedings already exist.

For courts and the wider mass tort bar. MDL 3140 is becoming a reference case for how to manage a partial global settlement. The techniques on display — resetting rather than vacating the evidentiary hearing, substituting pilot plaintiffs to preserve an adversary, coordinating through a joint agenda letter copied to state courts — are portable to any MDL where a negotiated matrix will leave a meaningful excluded population. The Ozempic and GLP-1 docket in the Eastern District of Pennsylvania is approaching the same gatekeeping question without a settlement in place; the contrast between the two is likely to shape how both are read.

Frequently asked questions

Has the Depo-Provera MDL causation ruling been issued?

No. The Rule 702 general causation motions in MDL No. 3140 were argued at a hearing in Pensacola on 27 July 2026 and taken under advisement by Judge M. Casey Rodgers. No ruling had issued as of 18 September 2026, and no decision date has been announced.

Who is left out of the Depo-Provera settlement?

Roughly 20% of the plaintiffs pending in the MDL — approximately 1,280 of the 6,403 actions on file as of 1 September 2026 — are expected to fall outside the eligibility criteria negotiated in the Master Settlement Agreement. The criteria themselves are confidential. Exclusion typically reflects exposure duration, diagnosis documentation, product identification or timeliness, not the strength of the underlying scientific theory.

What happens to non-eligible Depo-Provera claims if the causation experts are excluded?

Summary judgment would ordinarily follow. Plaintiffs who did not seek leave to offer their own general causation experts or additional briefing are bound by the court's ruling, so an exclusion order would leave that population unable to prove the first element of a products claim in the federal forum. Claims in state courts applying a different evidentiary standard are not directly bound.

When is the Depo-Provera settlement registration deadline?

Registration is expected to close in November 2026, with a deadline reported as 30 November 2026. BrownGreer PLC has administered the program since its appointment on 5 August 2026. First payments are projected for the first quarter of 2027.

How much is the Depo-Provera settlement worth?

No aggregate figure has been disclosed. The Master Settlement Agreement is confidential and its tier structure, medical proof requirements and individual allocations have not been published. Per-claim ranges circulating on firm websites are estimates offered by those firms, not terms released by the parties or the court.

Is Pfizer's preemption defense still live?

Yes. Pfizer's motion for summary judgment on federal preemption — arguing that failure-to-warn and design defect claims are barred because the FDA rejected an earlier meningioma warning proposal — remains pending before Judge Rodgers, who postponed the ruling. The FDA's approval of a revised meningioma warning in December 2025 complicates the defense, and the question of when newly acquired information existed overlaps directly with the Rule 702 fight.

Will there be a Depo-Provera trial in December 2026?

No. The 7 December 2026 trial date in Blonski v. Pfizer, the first pilot case, was vacated along with the remaining bellwether deadlines after the parties reported a global settlement in principle in June 2026. Three new pilot plaintiffs have been substituted for the original five, but no trial date has been set for them.